Curative Biotechnology Announces Completion of IND Enabling Reformulated Metformin HCL Eye Drop Study
05. Januar 2023 07:50 ET
|
Curative Biotechnology, Inc.
Boca Raton, FL, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company focused on novel treatments...
Curative Biotechnology Announces Intent to Uplist to NYSE American Exchange
27. September 2022 07:00 ET
|
Curative Biotechnology, Inc.
Boca Raton, FL, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development-stage biomedical company focused on novel treatments...
Curative Biotechnology Inc. Adds Biotech Veteran Lawrence S. Zaslow to Board of Directors
16. Juni 2022 09:50 ET
|
Curative Biotechnology, Inc.
Appointment of Independent Director Builds Upon Biotech Expertise Boca Raton, FL, June 16, 2022 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a...
Curative Biotechnology, Inc. Appoints Cary Sucoff to Board of Directors
12. Mai 2022 09:30 ET
|
Curative Biotechnology, Inc.
Appointment of Independent Director Adds to Financial Expertise on Board Boca Raton, FL, May 12, 2022 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the...
Curative Biotechnology Announces Cooperative Research and Development Agreement (CRADA) with the National Eye Institute (NEI) for Clinical Evaluation of its Proprietary Ocular Metformin Formulation in Age-Related Macular Degeneration
21. März 2022 09:50 ET
|
Curative Biotechnology, Inc.
Emily Y. Chew, M.D. of the National Eye Institute Assigned Principal Investigator Boca Raton, FL, March 21, 2022 (GLOBE NEWSWIRE) -- Curative Biotechnology, Inc. (OTC: CUBT) (“Curative” or the...
[UPDATED] CURATIVE BIOTECHNOLOGY ANNOUNCES OCULAR TOLERANCE EVALUATION OF METFORMIN EYE DROP FORMULATIONS FOR TREATMENT OF MACULAR DEGENERATION
24. November 2021 15:05 ET
|
Curative Biotechnology, Inc.
Company’s First In-license Pipeline Product to Enter Pre-clinical Studies Boca Raton, FL, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Curative Biotechnology, Inc. (OTC: CUBT) (“Curative Biotech” or the...
CURATIVE BIOTECHNOLOGY ANNOUNCES OCULAR TOLERANCE EVALUATION OF METFORMIN EYE DROP FORMULATIONS FOR TREATMENT OF MACULAR DEGENERATION
24. November 2021 10:00 ET
|
Curative Biotechnology, Inc.
Company’s First In-license Pipeline Product to Enter Pre-clinical Studies Boca Raton, FL, Nov. 24, 2021 (GLOBE NEWSWIRE) -- Curative Biotechnology, Inc. (OTC: CUBT) (“Curative Biotech” or the...
CURATIVE BIOTECHNOLOGY ANNOUNCES DR. CATHERINE SOHN AS SPECIAL ADVISOR TO BOARD AND CEO
12. Oktober 2021 10:12 ET
|
Curative Biotechnology, Inc.
Dr. Sohn to Oversee Development of Next Gen COVID-19 Vaccine to Treat Kidney Failure Patients, Late-Stage Rabies Therapeutic and Age-related Macular Degeneration Boca Raton, FL, Oct. 12, 2021 ...
Curative Biotechnology, Inc. Appoints Marc Drimer, CPA to Board of Directors as Independent Director and Chairman of Audit Committee
15. Juli 2021 10:00 ET
|
Curative Biotechnology, Inc.
Boca Raton, FL, July 15, 2021 (GLOBE NEWSWIRE) -- Curative Biotechnology Inc. (OTC: CUBT) (“Curative Biotech” or the “Company”), a development stage biomedical company focused on novel therapies for...
Curative Biotechnology, Inc. Announces Trading Symbol Change to “CUBT”
29. April 2021 10:12 ET
|
Curative Biotechnology, Inc.
Kapil Bharti, Ph.D. and Dimiter Dimitrov, Ph.D. Join Scientific and Clinical Advisory Board Boca Raton, FL, April 29, 2021 (GLOBE NEWSWIRE) -- Curative Biotechnology, Inc. (OTC: CUBT) a...